Kori Wallace, M.D.

New Capabilities

As of September 2026: Leading zumilokibart's clinical program at AbbVie

Patients with moderate to severe atopic dermatitis on the mid-dose of zumilokibart hit 65.9% skin clearance at 16 weeks, versus 23.4% on placebo. AbbVie presented the Phase 2 results as a late-breaker at the European Academy of Dermatology and Venereology congress in Vienna on Sept. 30.

Updated Sep 30